Dear Silenseed Shareholders,

***With good Efficacy and Safety clinical results from Phase 2, Silenseed received FDA approval to initiate Phase 3, and are planning Kick-off at Q3-2021.***

## Clinical Development

Good news:

- KRAS-LODER converts more patients from non-Resectable to Resectable, 3 times better compared to control (27%. vs 9%).
- KRAS-LODER **specifically affects patients with large tumors,** showing a clear signal of LODER effect **(figure)**.
- We continue to see **very encouraging evidence of life extension, tumor response and pain reduction** (Statistically significant reduction in pain was noted in the subgroup who enrolled with high pain score (VAS > 4)




With such a strong signal, both in safety and in efficacy, we received a green light from the FDA to initiate a larger (316 patients) Phase 3trial that aims to support marketing approval.



**Silenseed Ltd** | 2 HaMa'ayan Street, Modi'in Technology Park, Modi'in 7177871, Israel
info@silenseed.com | https://www.silenseed.com/

## Quality:

We are scheduled to have a full quality inspection by the Israeli Minister of Health at April 25, 2021; that will support Phase 3 and later commercialization of our products (planned from 2024)

## Team:

**Silenseed has strengthened the team with great people including:**
Dr Eran Gefen (TEVA) as our VP BD;
Dr. Diana Gurevitch (VP Pre-clinical);
Eran Ovadya (CFO),
Patricia Erb (Clinical),
Michal Yaron (VP Regulatory Affair)

I wish to thank you very much for your continuous support in Silenseed. Without your support nothing of the above could become a reality.

Sincerely,

Amotz Shemi
Chief Executive Officer
Silenseed LTD



**Silenseed Ltd** | 2 HaMa'ayan Street, Modi'in Technology Park, Modi'in 7177871, Israel
info@silenseed.com | https://www.silenseed.com/